Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2 GBP
−52.85 M GBP
2.68 M GBP
210.61 M
About PURETECH HEALTH PLC ORD GBP0.01
Sector
Industry
CEO
Bharatt M. Chowrira
Website
Headquarters
Boston
Founded
2015
ISIN
GB00BY2Z0H74
FIGI
BBG009F3HD28
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PRTC is 171.2 GBX — it has increased by 5.68% in the past 24 hours. Watch PURETECH HEALTH PLC ORD GBP0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange PURETECH HEALTH PLC ORD GBP0.01 stocks are traded under the ticker PRTC.
PRTC stock has fallen by −1.15% compared to the previous week, the month change is a 10.59% rise, over the last year PURETECH HEALTH PLC ORD GBP0.01 has showed a 5.22% increase.
We've gathered analysts' opinions on PURETECH HEALTH PLC ORD GBP0.01 future price: according to them, PRTC price has a max estimate of 660.66 GBX and a min estimate of 355.70 GBX. Watch PRTC chart and read a more detailed PURETECH HEALTH PLC ORD GBP0.01 stock forecast: see what analysts think of PURETECH HEALTH PLC ORD GBP0.01 and suggest that you do with its stocks.
PRTC reached its all-time high on Dec 29, 2020 with the price of 447.6 GBX, and its all-time low was 110.0 GBX and was reached on Mar 1, 2017. View more price dynamics on PRTC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PRTC stock is 7.00% volatile and has beta coefficient of 2.20. Track PURETECH HEALTH PLC ORD GBP0.01 stock price on the chart and check out the list of the most volatile stocks — is PURETECH HEALTH PLC ORD GBP0.01 there?
Today PURETECH HEALTH PLC ORD GBP0.01 has the market capitalization of 409.86 M, it has decreased by −5.59% over the last week.
Yes, you can track PURETECH HEALTH PLC ORD GBP0.01 financials in yearly and quarterly reports right on TradingView.
PURETECH HEALTH PLC ORD GBP0.01 is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
PRTC earnings for the last half-year are −0.12 GBX per share, whereas the estimation was −0.24 GBX, resulting in a 50.50% surprise. The estimated earnings for the next half-year are −0.22 GBX per share. See more details about PURETECH HEALTH PLC ORD GBP0.01 earnings.
PURETECH HEALTH PLC ORD GBP0.01 revenue for the last half-year amounts to 227.79 K GBX, despite the estimated figure of 5.93 M GBX. In the next half-year revenue is expected to reach 23.99 M GBX.
PRTC net income for the last half-year is −33.03 M GBP, while the previous report showed −32.48 M GBP of net income which accounts for −1.70% change. Track more PURETECH HEALTH PLC ORD GBP0.01 financial stats to get the full picture.
No, PRTC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PURETECH HEALTH PLC ORD GBP0.01 EBITDA is −105.47 M GBP, and current EBITDA margin is −4.24 K%. See more stats in PURETECH HEALTH PLC ORD GBP0.01 financial statements.
Like other stocks, PRTC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PURETECH HEALTH PLC ORD GBP0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PURETECH HEALTH PLC ORD GBP0.01 technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PURETECH HEALTH PLC ORD GBP0.01 stock shows the sell signal. See more of PURETECH HEALTH PLC ORD GBP0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.